Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials.

about

Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials.

Item

http://www.wikidata.org/entity/Q41342037

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Bevacizumab combined with chem ...... randomized controlled trials.

@en

type

Item

label

Bevacizumab combined with chem ...... randomized controlled trials.

@en

prefLabel

Bevacizumab combined with chem ...... randomized controlled trials.

@en

P1476

Bevacizumab combined with chem ...... randomized controlled trials.

@en

P2093

Kai-Di Gao

http://www.w3.org/2001/XMLSchema#string

Shou-Bo Yang

http://www.w3.org/2001/XMLSchema#string

Shu-Jun Cheng

http://www.w3.org/2001/XMLSchema#string

Tao Jiang

http://www.w3.org/2001/XMLSchema#string

Wen-Bin Li

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Statistical aspects of the analysis of data from retrospective studies of disease

Practical methods for incorporating summary time-to-event data into meta-analysis

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

P304

57337-57344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.16924

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28915674

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5593645

http://www.w3.org/2001/XMLSchema#string